File Download
  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Article: Pandemic A/H1N1 2009 Influenza Virus-like Particles Elicited Higher and Broader Immune Responses than the Commercial Panenza Vaccine

TitlePandemic A/H1N1 2009 Influenza Virus-like Particles Elicited Higher and Broader Immune Responses than the Commercial Panenza Vaccine
Authors
KeywordsInfluenza virus
Virus-like particle
Panenza vaccine
BALB/c mice
Issue Date2014
PublisherDavid Publishing Company. The Journal's web site is located at http://www.davidpublishing.org/journals_info.asp?jId=1547
Citation
Journal of Pharmacy and Pharmacology, 2014, v. 2 n. 1, p. 50-58 How to Cite?
AbstractObjectives: The aim was to construct 2009 pandemic A/H1N1 influenza VLPs (virus-like particles) and compare the immunogenicity and protection efficacy with the commercial Panenza vaccine in BALB/c mouse model. Methods: VLPs derived from influenza A/Hong Kong/01/2009 (H1N1) virus were constructed by Bac-to-Bac baculovirus expression system. VLPs were purified by sucrose density gradient ultracentrifugation and then characterized by Western blotting analysis and transmission electron microscopy. After single dose vaccination with 3 µg of VLPs and equal amount of Panenza vaccine, the immune responses and efficacy of protection induced by VLPs were compared with those elicited by the Panenza vaccine in 6-8 week female BALB/c mice. Key findings: VLPs could induce higher antibody titer as determined by hemagglutinin inhibition and microneutralization assay. Furthermore, we demonstrated that VLPs induced better antibody response to neuraminidase. In addition, VLP vaccinated mice had stronger cell-mediated immune response. As a result, our VLPs conferred 100% protection while the Panenza vaccine only conferred 67% protection. Conclusion: From the results, we concluded that influenza VLPs are highly immunogenic and they are promising to be developed as an alternative strategy to vaccine production in order to control the spread of influenza viruses.
Persistent Identifierhttp://hdl.handle.net/10722/199182
ISSN

 

DC FieldValueLanguage
dc.contributor.authorZhang, Nen_US
dc.contributor.authorLin, Yen_US
dc.contributor.authorChen, Men_US
dc.contributor.authorLeung, HCen_US
dc.contributor.authorChan, CSen_US
dc.contributor.authorPoon, KMen_US
dc.contributor.authorZhou, Jen_US
dc.contributor.authorCheung, CYen_US
dc.contributor.authorLu, Len_US
dc.contributor.authorZheng, Ben_US
dc.date.accessioned2014-07-22T01:06:17Z-
dc.date.available2014-07-22T01:06:17Z-
dc.date.issued2014en_US
dc.identifier.citationJournal of Pharmacy and Pharmacology, 2014, v. 2 n. 1, p. 50-58en_US
dc.identifier.issn2328-2150-
dc.identifier.urihttp://hdl.handle.net/10722/199182-
dc.description.abstractObjectives: The aim was to construct 2009 pandemic A/H1N1 influenza VLPs (virus-like particles) and compare the immunogenicity and protection efficacy with the commercial Panenza vaccine in BALB/c mouse model. Methods: VLPs derived from influenza A/Hong Kong/01/2009 (H1N1) virus were constructed by Bac-to-Bac baculovirus expression system. VLPs were purified by sucrose density gradient ultracentrifugation and then characterized by Western blotting analysis and transmission electron microscopy. After single dose vaccination with 3 µg of VLPs and equal amount of Panenza vaccine, the immune responses and efficacy of protection induced by VLPs were compared with those elicited by the Panenza vaccine in 6-8 week female BALB/c mice. Key findings: VLPs could induce higher antibody titer as determined by hemagglutinin inhibition and microneutralization assay. Furthermore, we demonstrated that VLPs induced better antibody response to neuraminidase. In addition, VLP vaccinated mice had stronger cell-mediated immune response. As a result, our VLPs conferred 100% protection while the Panenza vaccine only conferred 67% protection. Conclusion: From the results, we concluded that influenza VLPs are highly immunogenic and they are promising to be developed as an alternative strategy to vaccine production in order to control the spread of influenza viruses.en_US
dc.languageengen_US
dc.publisherDavid Publishing Company. The Journal's web site is located at http://www.davidpublishing.org/journals_info.asp?jId=1547-
dc.relation.ispartofJournal of Pharmacy and Pharmacologyen_US
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subjectInfluenza virus-
dc.subjectVirus-like particle-
dc.subjectPanenza vaccine-
dc.subjectBALB/c mice-
dc.titlePandemic A/H1N1 2009 Influenza Virus-like Particles Elicited Higher and Broader Immune Responses than the Commercial Panenza Vaccineen_US
dc.typeArticleen_US
dc.identifier.emailChen, M: jiange@hkucc.hku.hken_US
dc.identifier.emailChan, CS: cschan@hku.hken_US
dc.identifier.emailPoon, KM: vinpoon@hku.hken_US
dc.identifier.emailZhou, J: jiezhou@hku.hken_US
dc.identifier.emailCheung, CY: chungey@hkucc.hku.hken_US
dc.identifier.emailLu, L: liweilu@hkucc.hku.hken_US
dc.identifier.emailZheng, B: bzheng@hkucc.hku.hken_US
dc.identifier.authorityZhou, J=rp01412en_US
dc.identifier.authorityCheung, CY=rp00404en_US
dc.identifier.authorityLu, L=rp00477en_US
dc.identifier.authorityZheng, B=rp00353en_US
dc.description.naturepublished_or_final_version-
dc.identifier.hkuros230911en_US
dc.identifier.volume2en_US
dc.identifier.issue1en_US
dc.identifier.spage50en_US
dc.identifier.epage58en_US
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats